Searched for
NOVARTIS PHARMACEUTICALS
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...
- Citi sees India IPOs hitting fresh records despite challengesIndian initial public offerings are poised for a strong comeback in the latter half of the year. Citigroup anticipates deal volumes to meet...
- Novartis sharpening India strategy as a pure-play innovatorNovartis India country president and managing director Amitabh Dube said India is gradually moving beyond its traditional role as a clinica...
- DeepMind CEO Demis Hassabis’ Isomorphic Labs raises $2.1 billion led by Thrive CapitalAI-driven drug discovery firm Isomorphic Labs secured a massive $2.1 billion in Series B funding. This capital will fuel the expansion of t...
- Google’s Isomorphic Labs to raise over $2 billion in new fundingAlphabet's AI drug discovery firm, Isomorphic Labs, is reportedly close to securing over $2 billion in new funding, led by Thrive Capital. ...
- Anthropic appoints Indian-origin Novartis CEO Vas Narasimhan to its boardAnthropic’s Long-Term Benefit Trust is an independent governance body, designed to insulate key decisions as it scales its frontier AI syst...
- Delhi HC restrains generic pharma firms from making, selling patent drug of NovartisThe plea said the plaintiff through a press release of January 28, 2019 issued by the defendant came to know about its act in launching a p...
- Novartis pays $678 million to resolve suit over sham doctor outingsThe settlement of the lawsuit was announced by Acting Manhattan U.S. Attorney Audrey Strauss, who said the company splurged on "speaking fe...
- Jawed Zia quits Abbott IndiaJawed had joined the role in June 2018 after quitting Novartis within 15 days of being appointed to lead the Swiss drug company’s India bus...
- Novartis India appoints Milan Paleja as vice chairman and MDPaleja is currently country president at Novartis in India and is also responsible for the pharmaceuticals business in the country. He is a...
- Milan Paleja to head Novartis India's pharmaceuticals businessPaleja, previously president and head of pharmaceuticals for Novartis Indonesia, will also head Novartis India's pharmaceutical business, a...
- GSK Pharma completes deal with Novartis HealthcareDrug firm GlaxoSmithKline Pharmaceuticals has acquired Novartis' vaccines business and divested its marketed oncology portfolio to Novartis...
- Competition Commission of India clears Novartis-GlaxoSmithKline pharma dealThe multi-layered deal involves UK-based GlaxoSmithKline acquiring Novartis's vaccine biz, while latter would purchase GSK's cancer drugs p...
- Alembic Pharmaceuticals soars on patent settlement case with NovartisShares of Alembic Pharma surged by over 4% after the co said it along with Breckenridge Pharma Inc, USA has settled a patent case with Nova...
- Novartis fined $250 mn for discriminationA Novartis pharmaceuticals unit was ordered to pay $250 million in punitive damages to a group of 5,600 female employees after losing a gen...
- Novartis to cut 2,500 jobs worldwide by 2010Novartis AG will cut 2,500 jobs worldwide by 2010 in an attempt to save $1.6 bn, the drugmaker said in becoming the latest major pharmaceut...
- Nestle buys baby food biz off NovartisSwiss food giant Nestle is buying the Gerber baby food business off pharma major Novartis for $5.5 bn.
Load More
